The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy

Aim. To study the mechanisms, features of clinical manifestations and predicting of cardiotoxicity resulting from anthracycline chemotherapy.Material and methods. We examined 176 women with breast cancer who received anthracycline antibiotics as part of polychemotherapeutic (PCT) treatment. Patients...

Full description

Bibliographic Details
Main Authors: A. T. Teplyakov, S. N. Shilov, A. A. Popova, E. N. Berezikova, M. N. Neupokoeva, E. V. Grakova, K. V. Kopeva
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2019-03-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/749
id doaj-e0a2ce384d0a407f807fd553798648f8
record_format Article
spelling doaj-e0a2ce384d0a407f807fd553798648f82021-07-28T13:51:05Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252019-03-0118112713310.15829/1728-8800-2019-1-127-133610The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapyA. T. Teplyakov0S. N. Shilov1A. A. Popova2E. N. Berezikova3M. N. Neupokoeva4E. V. Grakova5K. V. Kopeva6Research Institute of CardiologyNovosibirsk State Medical UniversityNovosibirsk State Medical UniversityNovosibirsk State Medical UniversityNovosibirsk State Medical UniversityResearch Institute of CardiologyResearch Institute of CardiologyAim. To study the mechanisms, features of clinical manifestations and predicting of cardiotoxicity resulting from anthracycline chemotherapy.Material and methods. We examined 176 women with breast cancer who received anthracycline antibiotics as part of polychemotherapeutic (PCT) treatment. Patients were divided into 2 groups: with the development of cardiotoxic remodeling — group 1 (n=52) and with preserved heart function — group 2 (n=124). We conducted echocardiographic (EchoCG) tests before the start, during and after anthracycline chemotherapy. In the serum after the termination of PCT treatment, the concentrations of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and soluble Fas ligand (sFas-L) were determined.Results. Analysis of EchoCG parameters in patients after 12 months of PCT finish, showed a significant difference in the final systolic and end diastolic sizes, as well as a significant decrease in the left ventricular ejection fraction in group 1 compared with those before the start of treatment. A direct correlation was found between the end-systolic and end-diastolic volumes and inverse correlation between left ventricular ejection fraction and the resulting summary dose of doxorubicin. EchoCG changes in women of group 1 after the first course of PCT treatment were recorded in 49% of cases and 11% of cases — in group 2. The concentrations of sFas-L and NT-proBNP after PCT therapy finish in group 1 were significantly higher compared with group 2. Patients with significantly elevated NT-proBNP levels were had a high risk of heart disease developing during 12 months follow-up. A high concentration of NT-proBNP is a predictor of cardiovascular complications, which is more sensitive than EchoCG.Conclusion. Fas-associated apoptosis plays an important role in the pathogenesis of anthracycline cardiotoxicity. NT-proBNP may be an important biomarker for cardiotoxicity development, which already effective when EchoCG or clinical signs is absent.https://cardiovascular.elpub.ru/jour/article/view/749cardiomyopathycardiotoxicityanthracyclineschemotherapybiomarkersnatriuretic peptidesfas-ligandprognosis
collection DOAJ
language Russian
format Article
sources DOAJ
author A. T. Teplyakov
S. N. Shilov
A. A. Popova
E. N. Berezikova
M. N. Neupokoeva
E. V. Grakova
K. V. Kopeva
spellingShingle A. T. Teplyakov
S. N. Shilov
A. A. Popova
E. N. Berezikova
M. N. Neupokoeva
E. V. Grakova
K. V. Kopeva
The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
Кардиоваскулярная терапия и профилактика
cardiomyopathy
cardiotoxicity
anthracyclines
chemotherapy
biomarkers
natriuretic peptides
fas-ligand
prognosis
author_facet A. T. Teplyakov
S. N. Shilov
A. A. Popova
E. N. Berezikova
M. N. Neupokoeva
E. V. Grakova
K. V. Kopeva
author_sort A. T. Teplyakov
title The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
title_short The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
title_full The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
title_fullStr The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
title_full_unstemmed The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
title_sort prognostic value of the nt-probnp biomarkers and fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
publisher «SILICEA-POLIGRAF» LLC
series Кардиоваскулярная терапия и профилактика
issn 1728-8800
2619-0125
publishDate 2019-03-01
description Aim. To study the mechanisms, features of clinical manifestations and predicting of cardiotoxicity resulting from anthracycline chemotherapy.Material and methods. We examined 176 women with breast cancer who received anthracycline antibiotics as part of polychemotherapeutic (PCT) treatment. Patients were divided into 2 groups: with the development of cardiotoxic remodeling — group 1 (n=52) and with preserved heart function — group 2 (n=124). We conducted echocardiographic (EchoCG) tests before the start, during and after anthracycline chemotherapy. In the serum after the termination of PCT treatment, the concentrations of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and soluble Fas ligand (sFas-L) were determined.Results. Analysis of EchoCG parameters in patients after 12 months of PCT finish, showed a significant difference in the final systolic and end diastolic sizes, as well as a significant decrease in the left ventricular ejection fraction in group 1 compared with those before the start of treatment. A direct correlation was found between the end-systolic and end-diastolic volumes and inverse correlation between left ventricular ejection fraction and the resulting summary dose of doxorubicin. EchoCG changes in women of group 1 after the first course of PCT treatment were recorded in 49% of cases and 11% of cases — in group 2. The concentrations of sFas-L and NT-proBNP after PCT therapy finish in group 1 were significantly higher compared with group 2. Patients with significantly elevated NT-proBNP levels were had a high risk of heart disease developing during 12 months follow-up. A high concentration of NT-proBNP is a predictor of cardiovascular complications, which is more sensitive than EchoCG.Conclusion. Fas-associated apoptosis plays an important role in the pathogenesis of anthracycline cardiotoxicity. NT-proBNP may be an important biomarker for cardiotoxicity development, which already effective when EchoCG or clinical signs is absent.
topic cardiomyopathy
cardiotoxicity
anthracyclines
chemotherapy
biomarkers
natriuretic peptides
fas-ligand
prognosis
url https://cardiovascular.elpub.ru/jour/article/view/749
work_keys_str_mv AT atteplyakov theprognosticvalueofthentprobnpbiomarkersandfasligandinassessingtheriskofcardiotoxicityofanthracyclinechemotherapy
AT snshilov theprognosticvalueofthentprobnpbiomarkersandfasligandinassessingtheriskofcardiotoxicityofanthracyclinechemotherapy
AT aapopova theprognosticvalueofthentprobnpbiomarkersandfasligandinassessingtheriskofcardiotoxicityofanthracyclinechemotherapy
AT enberezikova theprognosticvalueofthentprobnpbiomarkersandfasligandinassessingtheriskofcardiotoxicityofanthracyclinechemotherapy
AT mnneupokoeva theprognosticvalueofthentprobnpbiomarkersandfasligandinassessingtheriskofcardiotoxicityofanthracyclinechemotherapy
AT evgrakova theprognosticvalueofthentprobnpbiomarkersandfasligandinassessingtheriskofcardiotoxicityofanthracyclinechemotherapy
AT kvkopeva theprognosticvalueofthentprobnpbiomarkersandfasligandinassessingtheriskofcardiotoxicityofanthracyclinechemotherapy
AT atteplyakov prognosticvalueofthentprobnpbiomarkersandfasligandinassessingtheriskofcardiotoxicityofanthracyclinechemotherapy
AT snshilov prognosticvalueofthentprobnpbiomarkersandfasligandinassessingtheriskofcardiotoxicityofanthracyclinechemotherapy
AT aapopova prognosticvalueofthentprobnpbiomarkersandfasligandinassessingtheriskofcardiotoxicityofanthracyclinechemotherapy
AT enberezikova prognosticvalueofthentprobnpbiomarkersandfasligandinassessingtheriskofcardiotoxicityofanthracyclinechemotherapy
AT mnneupokoeva prognosticvalueofthentprobnpbiomarkersandfasligandinassessingtheriskofcardiotoxicityofanthracyclinechemotherapy
AT evgrakova prognosticvalueofthentprobnpbiomarkersandfasligandinassessingtheriskofcardiotoxicityofanthracyclinechemotherapy
AT kvkopeva prognosticvalueofthentprobnpbiomarkersandfasligandinassessingtheriskofcardiotoxicityofanthracyclinechemotherapy
_version_ 1721270829607550976